Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Sino-American Firm Raises $100 Million
by Michael McCoy
April 11, 2011
| A version of this story appeared in
Volume 89, Issue 15
Ascietis, a new specialty therapeutics firm based in the U.S. and China, says it has commitments for $100 million in financing from private investors in China and elsewhere. Led by Jinzi J. Wu, who was previously vice president of HIV drug discovery at GlaxoSmithKline, Ascietis plans to build a near-term business by in-licensing compounds for the Chinese market and a longer term business based on its own discoveries in the fields of cancer and infectious diseases. It will have facilities in Chapel Hill, N.C., and Hangzhou, China.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter